Kyverna Therapeutics (KYTX) Competitors $3.85 +0.27 (+7.54%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$3.92 +0.07 (+1.79%) As of 08/22/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KYTX vs. ORGO, MAZE, KROS, TRML, ORKA, TYRA, RZLT, ANAB, KOD, and XNCRShould you be buying Kyverna Therapeutics stock or one of its competitors? The main competitors of Kyverna Therapeutics include Organogenesis (ORGO), Maze Therapeutics (MAZE), Keros Therapeutics (KROS), Tourmaline Bio (TRML), Oruka Therapeutics (ORKA), Tyra Biosciences (TYRA), Rezolute (RZLT), AnaptysBio (ANAB), Kodiak Sciences (KOD), and Xencor (XNCR). These companies are all part of the "pharmaceutical products" industry. Kyverna Therapeutics vs. Its Competitors Organogenesis Maze Therapeutics Keros Therapeutics Tourmaline Bio Oruka Therapeutics Tyra Biosciences Rezolute AnaptysBio Kodiak Sciences Xencor Kyverna Therapeutics (NASDAQ:KYTX) and Organogenesis (NASDAQ:ORGO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership. Is KYTX or ORGO more profitable? Kyverna Therapeutics has a net margin of 0.00% compared to Organogenesis' net margin of -1.92%. Organogenesis' return on equity of -0.37% beat Kyverna Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kyverna TherapeuticsN/A -64.98% -56.17% Organogenesis -1.92%-0.37%-0.20% Which has higher valuation and earnings, KYTX or ORGO? Organogenesis has higher revenue and earnings than Kyverna Therapeutics. Organogenesis is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKyverna Therapeutics$7.03M23.69-$127.48M-$3.68-1.05Organogenesis$482.04M1.29$860K-$0.14-34.93 Do institutionals and insiders hold more shares of KYTX or ORGO? 18.1% of Kyverna Therapeutics shares are held by institutional investors. Comparatively, 49.6% of Organogenesis shares are held by institutional investors. 22.0% of Kyverna Therapeutics shares are held by insiders. Comparatively, 33.0% of Organogenesis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more risk & volatility, KYTX or ORGO? Kyverna Therapeutics has a beta of 3.05, suggesting that its stock price is 205% more volatile than the S&P 500. Comparatively, Organogenesis has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500. Do analysts prefer KYTX or ORGO? Kyverna Therapeutics presently has a consensus price target of $15.60, indicating a potential upside of 305.19%. Organogenesis has a consensus price target of $7.50, indicating a potential upside of 53.37%. Given Kyverna Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Kyverna Therapeutics is more favorable than Organogenesis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kyverna Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Organogenesis 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Does the media favor KYTX or ORGO? In the previous week, Kyverna Therapeutics had 18 more articles in the media than Organogenesis. MarketBeat recorded 18 mentions for Kyverna Therapeutics and 0 mentions for Organogenesis. Organogenesis' average media sentiment score of 1.76 beat Kyverna Therapeutics' score of 0.45 indicating that Organogenesis is being referred to more favorably in the news media. Company Overall Sentiment Kyverna Therapeutics Neutral Organogenesis Very Positive SummaryKyverna Therapeutics beats Organogenesis on 9 of the 17 factors compared between the two stocks. Get Kyverna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KYTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KYTX vs. The Competition Export to ExcelMetricKyverna TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$166.50M$3.12B$5.83B$9.78BDividend YieldN/A2.23%4.40%4.05%P/E Ratio-1.0521.0031.3026.05Price / Sales23.69357.30455.25117.77Price / CashN/A44.5038.0259.36Price / Book0.908.129.536.60Net Income-$127.48M-$54.72M$3.26B$265.65M7 Day Performance9.69%2.62%2.14%2.01%1 Month Performance-11.09%2.68%2.81%-0.33%1 Year Performance-52.41%10.93%30.70%19.04% Kyverna Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KYTXKyverna Therapeutics2.7165 of 5 stars$3.85+7.5%$15.60+305.2%-51.6%$166.50M$7.03M-1.0596News CoverageAnalyst ForecastAnalyst RevisionHigh Trading VolumeORGOOrganogenesis4.2862 of 5 stars$4.58-3.2%$7.50+63.8%+77.8%$600.04M$482.04M-32.71950Positive NewsMAZEMaze TherapeuticsN/A$13.35-1.1%$25.60+91.8%N/A$591.99M$167.50M0.00121KROSKeros Therapeutics3.0133 of 5 stars$14.52+0.3%$30.00+106.6%-65.2%$588.11M$3.55M46.84100News CoverageTRMLTourmaline Bio2.3532 of 5 stars$22.17-1.8%$50.14+126.2%+63.7%$579.72MN/A-6.4644ORKAOruka Therapeutics2.2917 of 5 stars$15.25-0.8%$40.38+164.8%N/A$571.13MN/A-5.43N/AAnalyst RevisionTYRATyra Biosciences2.2708 of 5 stars$10.81+0.7%$30.83+185.2%-46.2%$569.66MN/A-6.0720News CoverageAnalyst ForecastRZLTRezolute3.1768 of 5 stars$6.55+0.8%$12.20+86.3%+64.7%$565.47MN/A-5.7040ANABAnaptysBio3.0099 of 5 stars$20.02-0.6%$46.13+130.4%-45.8%$563.86M$123.16M-4.47100KODKodiak Sciences3.1932 of 5 stars$11.25+6.4%$11.75+4.4%+280.6%$558.33MN/A-2.9690Analyst RevisionXNCRXencor3.6887 of 5 stars$7.81+1.7%$26.43+238.4%-49.6%$557.03M$146.93M-3.25280News CoverageAnalyst Forecast Related Companies and Tools Related Companies ORGO Alternatives MAZE Alternatives KROS Alternatives TRML Alternatives ORKA Alternatives TYRA Alternatives RZLT Alternatives ANAB Alternatives KOD Alternatives XNCR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KYTX) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kyverna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kyverna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access